RxDoctor Payments Data

Oleg Ivanov, MD

Cardiovascular Disease · Casper, WYNPI 1437311222

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 73.0% of it on its own, with 6 other manufacturers making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in WY, where the typical reported total is $1,181.

$765in general payments, 2019–2025

Across 37 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$559
  • Novartis$103
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$32
  • Medtronic$27
  • Heartflow, Inc.$17
  • E.r. Squibb & Sons, L.L.C.$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$765 in reported general payments places this provider in the 40th percentile of 22 cardiovascular disease providers in Wyoming.

See all cardiovascular disease providers in Wyoming

Medicare billing

Part B allowed, 2024
$710,722
Medicare patients
2,560
Services billed
7,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban579$495,242
EntrestoSacubitril/Valsartan228$166,621
XareltoRivaroxaban68$67,669
JardianceEmpagliflozin49$35,085
FarxigaDapagliflozin Propanediol21$22,087
Repatha SureclickEvolocumab13$6,975
Metoprolol Succinate473$5,554
Atorvastatin Calcium596$4,783
Dofetilide20$3,454
Flecainide Acetate118$3,325
Amlodipine Besylate399$2,742
Carvedilol432$2,719
Potassium Chloride153$2,316
Digoxin89$1,793
Lisinopril284$1,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$495,242579 claims
NovartisEntresto$103$166,621228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 22 cardiovascular disease providers in Wyoming.

Other cardiovascular disease in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →